CompletedNot applicableNCT01615484

Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant Suitability

Studying Alpha-1-antitrypsin deficiency

Last synced from ClinicalTrials.gov May 5, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: University of North Carolina, Chapel Hill
Principal Investigator: Thomas M. Egan, MD, MSc.
UNC-Chapel Hill
Intervention: Transplantation of lungs obtained from Non-Heart-Beating Donors (NHBDs) after ex-vivo perfusion w/ STEEN Solution™(procedure)
Enrollment: 24 enrolled
Eligibility: 15 years · All sexes
Timeline: 2013 – 2017

Study locations (2)

UNC-Chapel Hill, Chapel Hill, North Carolina, United States
Duke University Medical Center, Durham, North Carolina, United States

Collaborators

Duke University · National Heart, Lung, and Blood Institute (NHLBI) · Vitrolife · XVIVO Perfusion

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01615484 on ClinicalTrials.gov

Other trials for Alpha-1-antitrypsin deficiency

Additional recruiting or active studies for the same condition.

See all trials for Alpha-1-antitrypsin deficiency →

← Back to all trials